Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil and Rituximab for Primary Treatment of Extensive Chronic Graft-versus-host Disease
NCT06046248Phase 2Suspended
- Sponsor
- Northside Hospital
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belumosudil, rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Northside Hospital. Started Jan 2024; status: suspended.
02
Drugs
belumosudilrituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06046248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046248.